{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:07:50Z","timestamp":1789020470781,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have improved cancer outcomes but can cause immune\u2010related adverse effects (irAEs), including acute kidney injury (AKI). Limited Australian data exists regarding ICI\u2010associated AKI (ICI\u2010AKI). This observational study is aimed to describe the incidence, risk factors, and outcomes of ICI\u2010AKI at Southern Adelaide Local Health Network (SALHN), South Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients receiving ICI therapy at SALHN between January 2020 and December 2023 were included. Clinical and laboratory data were collected from electronic medical records. ICI\u2010AKI was defined as AKI that led to the delay or discontinuation of ICI therapy due to clinical concern, biopsy\u2010proven ICI\u2010related tubulointerstitial nephritis, or corticosteroid\u2010treated suspected ICI\u2010AKI. Data on kidney biopsy findings, corticosteroid use, ICI rechallenge, AKI recurrence, and renal recovery were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 507 patients, 58 (11.4%) developed AKI, with 11 cases (2.2%) attributed to ICIs. Ipilimumab use and lower baseline eGFR were associated with higher AKI and ICI\u2010AKI risk, while durvalumab was associated with lower AKI risk. Median time to AKI onset was 83 days post\u2010first ICI cycle. Corticosteroids were initiated in eight patients for a median of 154 days. Four patients underwent kidney biopsy (median 106\u00a0days post\u2010AKI), all showing tubulointerstitial nephritis. Four patients were rechallenged with ICIs; one had recurrent AKI. One patient required dialysis, and two achieved complete renal recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this first Australian study examining all forms of cancer, ICI\u2010AKI occurred infrequently, but had a significant clinical impact. Ipilimumab exposure and impaired baseline kidney function were key risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.70174","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:56:47Z","timestamp":1789019807000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitor\u2010Associated Acute Kidney Injury: A Single\u2010Centre Study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1847-2244","authenticated-orcid":false,"given":"Jyothirmaye","family":"Kuppa","sequence":"first","affiliation":[{"name":"Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Rao","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Juneja","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Milton","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Ullah","sequence":"additional","affiliation":[{"name":"Flinders University  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353339"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11071187"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.09.017"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000455014"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574271"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00990119"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1173952"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12396"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102021\u2010003467"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad035"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac109"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882\u2010023\u201003171\u20109"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac194"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00686"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2238823"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425\u2010018\u20100478\u20108"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw382"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy100"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102022\u2010005646"},{"key":"e_1_2_7_25_1","unstructured":"\u201cManagement of Immune\u2010Related Adverse Events (irAEs) | eviQ\u201d accessed July 15 2026.https:\/\/www.eviq.org.au\/clinical\u2010resources\/side\u2010effect\u2010and\u2010toxicity\u2010management\/immunological\/1993\u2010management\u2010of\u2010immune\u2010related\u2010adverse\u2010events#renal\u2010toxicity."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.62347\/JECH8448"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000152019"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107325"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70174","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:56:49Z","timestamp":1789019809000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":27,"alternative-id":["10.1111\/ajco.70174"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70174","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"2026-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajco.70174"}}